Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blinded, Active-controlled, Multicentered Phase III Trial to Assess the Efficacy and Safety of Minodronate Tablets in Postmenopausal Women With Osteoporosis

NCT05305183 is registered in ClinicalTrials.gov with Shandong New Time Pharmaceutical Co., LTD as lead sponsor.

NCT NCT05305183
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05305183 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blinded, Active-controlled, Multicentered Phase III Trial to Assess the Efficacy and Safety of Minodronate Tablets in Postmenopausal Women With Osteoporosis
Lead sponsor
Shandong New Time Pharmaceutical Co., LTD
Phase
Phase 3
Overall status
Unknown status
Start date
May 31, 2022
Completion date
May 31, 2024
Enrollment
330 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

osteoporosis